1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced the publication of PEGASUS (TM), a multimodal AI model that achieves state-of-the-art ...

PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill ...

Insamo Inc., founded in 2022 to combine machine-learning capabilities, high-throughput screening and genetic engineering to create orally administered membrane-permeable cyclic peptides across a range ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for elamipretide in the treatment of Barth syndrome, a rare mitochondrial disease.

CycPeptMPDB, a novel database—created by Tokyo Tech researchers—focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds.

Peptides are short chains of amino acids that act as biological messengers, telling skin cells and tissues how to repair, ...

The Tat-SIRT5-CTM peptide specifically blocked the interaction of SIRT5 with ANXA1, led to SIRT5 degradation and thereby inhibiting SIRT5-mediated desuccinylation of ANXA1, which in turn alleviated ...

BOSTON, January 06, 2026--1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today ...

To understand the focus of startup Insamo Inc., one need look no further than its name, which co-founder and CEO Timothy Craven described as “portmanteau of ‘internally satisfied molecules,’” ...